Betschel Stephen D, Warrington Richard J, Schellenberg Robert
St Michael's Hospital and the University of Toronto, 30 Bond St, Toronto, ON M5B 1W8 Canada.
Head, Section of Allergy & Immunology, Department of Internal Medicine, University of Manitoba, Winnipeg Health Science Center, GC319 820 Sherbrook St, Winnipeg, MB R3A 1R9 Canada.
Allergy Asthma Clin Immunol. 2016 Jul 27;12:32. doi: 10.1186/s13223-016-0138-9. eCollection 2016.
In Canada, intravenous immune globulin (IVIg) products are licensed for six disease indications, however it has been demonstrated that patients with a number of other conditions also benefit from IVIg. Here we report the routine clinical use of Octagam(®) 10 % across three Canadian institutions. A total of 135 patients were treated with Octagam(®), for conditions represented by five distinct indication groups. The results of this review indicate that Octagam(®) has been well adopted and is prescribed to Canadian patients similar to other IVIg products. In alignment with current practices, 85 % of Octagam's utilization was classified as appropriate based on Canadian IVIg guidelines.
在加拿大，静脉注射免疫球蛋白（IVIg）产品有六种疾病适应症获得许可，然而已证明许多其他病症的患者也能从IVIg中获益。在此，我们报告Octagam(®) 10%在加拿大三个机构的常规临床应用情况。共有135例患者接受了Octagam(®)治疗，涉及五个不同适应症组所代表的病症。本综述结果表明，Octagam(®)已被广泛采用，并且与其他IVIg产品一样被开给加拿大患者。根据加拿大IVIg指南，与当前做法一致，Octagam使用的85%被归类为适当。
